StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Sumeet Bagadia, Choice Broking

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

bySumeet Bagadia, Choice BrokingHorizon: NA (inferred Swing (≤2wk))17 Oct 2026via LiveMint Markets

Entry₹1,232Inferred
Target₹1,365
Total upside +10.80%
Stop loss₹1,167-5.28% risk
CMP₹1,242.5Just now
Active+0.85%+9.86%upside left 13d left
Follow Sumeet Bagadia for new calls(29% target hit, 400 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 1 other Swing call on DRREDDYSee 78 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 20 Oct, 2:40 pm IST
2 supporting2 neutral5 opposing
Supports the BUY call (2)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·19 Oct · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·19 Oct · yesterday

Neutral / worth noting (2)

Q2 FY27 results scheduled — board meets 23 Oct 2026

BSE · Board Meeting·In 3 days

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · yesterday

(opens in new tab)
Weighs against the BUY call (5)

MACD below its signal line — bearish momentum

Technicals · macd·20 Oct · today

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 1w ago

(opens in new tab)

A pre-approval inspection ends with USFDA observations at Dr. Reddy’s (RDY).

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Dr. Reddy's USFDA PAI Inspection: Form 483 at FTO-11 Plant

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Pomerantz LLP investigates Dr. Reddy's over semaglutide-linked losses

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Sumeet Bagadia, Choice Broking

Every call and its outcome